Key Points
- Director Jeffrey Bluestone sold 5,000 Gilead shares for $725,100 under a pre-arranged Rule 10b5-1 trading plan, reducing his direct holdings by 33.19% to 10,066 shares.
- Gilead reported quarterly revenue of $7.80 billion, ahead of estimates, while adjusted EPS of ($6.75) beat consensus by $0.50; revenue increased 10.6% year over year.
- The company declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a 2.2% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $158.04.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gilead Sciences Trading Up 1.9%
Shares of Gilead Sciences stock opened at $146.12 on Friday. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The stock has a market capitalization of $181.18 billion, a P/E ratio of -54.73 and a beta of 0.32. The company has a 50-day simple moving average of $131.97 and a 200 day simple moving average of $136.59. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 earnings per share. Research analysts expect that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences's payout ratio is currently -122.85%.
Institutional Investors Weigh In On Gilead Sciences
A number of institutional investors and hedge funds have recently made changes to their positions in GILD. Persistent Asset Partners Ltd bought a new position in Gilead Sciences in the second quarter valued at about $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences in the fourth quarter worth about $25,000. Kimelman & Baird LLC bought a new stake in Gilead Sciences during the 2nd quarter worth about $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 85 shares during the last quarter. Finally, Quattro Advisors LLC bought a new stake in Gilead Sciences during the 4th quarter worth about $26,000. Institutional investors own 83.67% of the company's stock.
Wall Street Analysts Forecast Growth
GILD has been the subject of a number of research reports. Weiss Ratings lowered Gilead Sciences from a "buy (b-)" rating to a "hold (c-)" rating in a research note on Tuesday, August 11th. Barclays reduced their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 29th. Leerink Partners lowered shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. HSBC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Finally, Daiwa Securities Group dropped their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a research note on Tuesday, May 19th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $158.04.
View Our Latest Research Report on GILD
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
